


## CLAIMS

1. A compound of the general formula (I) or a pharmaceutically acceptable acid addition salt thereof:

5



wherein

10

$R_1$ - $R_4$  are, independent of each other H;  $C_1$ - $C_6$  alkyl; halogen;  $NR_5R_6$ , wherein  $R_5$  and  $R_6$  are, independent of each other, H,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  acyl;  $OR_7$ , wherein  $R_7$  is H,  $C_1$ - $C_6$  alkyl or  $C_2$ - $C_6$  acyl; CN;  $COR_8$ , wherein  $R_8$  is H,  $C_1$ - $C_6$  alkyl or  $C_1$ - $C_6$  alkoxy;

15

A is  $CHR_9$ , wherein  $R_9$  is H,  $C_1$ - $C_6$  alkyl;

n is 1-3;

20

B is  $CHR_{10}$ , wherein  $R_{10}$  is H,  $C_1$ - $C_6$  alkyl;

m is 1 or 2;

25

D is O or S or optionally  $NR_{16}$ , wherein  $R_{16}$  is H,  $C_1$ - $C_6$  alkyl or  $C_2$ - $C_6$  acyl ;

E is  $CR_{11}R_{12}$  or  $NR_{13}$ , wherein  $R_{11}$  and  $R_{12}$  are, independent of each other, H or  $C_1$ - $C_6$  alkyl and wherein  $R_{13}$  is H or  $C_1$ - $C_6$  alkyl;

F is C<sub>1</sub>-C<sub>18</sub> alkyl, which is optionally mono- or di-unsaturated and is optionally substituted by alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, wherein, independent of each other, said C<sub>1</sub>-C<sub>18</sub> alkyl and optional substituents are optionally further substituted by one to three substituents  
5 independently selected from F, Cl, and Br;

with the proviso that,

10 if R<sub>1</sub> and R<sub>2</sub> are H, n is 2, m is 1, D is S, E is NH, F is 2-(4-chlorophenyl)ethyl or octyl, R<sub>3</sub> and R<sub>4</sub> are not both OH or OH and OCH<sub>3</sub>;  
if R<sub>1</sub> and R<sub>4</sub> are H, n is 2 or 3, m is 1, D is S, E is NH, F is 2-(4-chlorophenyl)ethyl or octyl, R<sub>2</sub> and R<sub>3</sub> are not both OH or OH and OCH<sub>3</sub>.

15 2. The compound of claim 1, wherein R<sub>9</sub> and R<sub>10</sub> are H.

3. The compound of claim 1, wherein at least one of R<sub>11</sub>, R<sub>12</sub> and R<sub>13</sub> is H.

4. The compound of claim 1, wherein R<sub>11</sub> and R<sub>13</sub> are H

20 5. The compound of claim 4, wherein R<sub>9</sub> and R<sub>10</sub> are H.

6. The compound of claim 5, wherein R<sub>12</sub> is H.

25 7. The compound of claim 1, wherein F is  $\omega$ -(C<sub>1</sub>-C<sub>3</sub>)R<sub>14</sub>, wherein R<sub>14</sub> is substituted or unsubstituted aryl or heteroaryl.

8. The compound of claim 7, wherein R<sub>14</sub> is mono-, di- or trisubstituted aryl or mono-, di- or trisubstituted heteroaryl, wherein said mono-, di- or trisubstitution is C<sub>1</sub>-C<sub>6</sub> alkyl; aryl; heteroaryl; halogen; hydroxy, C<sub>1</sub>-C<sub>3</sub> alkoxy; methylenedioxy;  
30 nitro; cyano; carboxy C<sub>1</sub>-C<sub>6</sub> alkyl; R<sub>15</sub>CO, wherein R<sub>15</sub> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl; amino; alkylamino, dialkylamino; fully or partially fluorinated C<sub>1</sub>-C<sub>6</sub> alkyl; with the proviso that, in case of di- or trisubstitution, the substituents are same or different.

9. The compound of claim 8, wherein at least one substituent in said mono-, di- or trisubstitution is selected from C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, F, Cl, Br, methyl, trifluoromethyl, nitro, and methoxy.

5 10. The compound of claim 8, wherein at least two substituents in said mono, di- or trisubstitution are selected from C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, F, Cl, Br, methyl, trifluoromethyl, nitro, and methoxy.

11. The compound of claim 1, wherein at least one of R<sub>1</sub>-R<sub>4</sub> is halogen.

10

12. The compound of claim 11, wherein said halogen is chloro or bromo.

13. The compound of claim 11, wherein at least one of R<sub>1</sub>-R<sub>4</sub> is hydroxy or methoxy.

15

14. The compound of claim 1, wherein at least one of R<sub>1</sub> and R<sub>4</sub> is halogen.

15. The compound of claim 14, wherein said halogen is chloro.

20 16. The compound of claim 1, wherein at least two of R<sub>1</sub>-R<sub>4</sub> are halogen.

17. The compound of claim 16, wherein each of said halogens is independently chloro or bromo.

25 18. The compound of claim 16, wherein said halogen is chloro.

19. The compound of claim 16, wherein at least one of R<sub>1</sub> and R<sub>4</sub> is halogen.

30 20. The compound of claim 16, wherein at least one of R<sub>1</sub>-R<sub>4</sub> is hydroxy or methoxy.

21. The compound of claim 20, wherein two of R<sub>1</sub>-R<sub>4</sub> are, independent of each other, hydroxy or methoxy or methylenedioxy.

22. The compound of claim 1, wherein at least one of R<sub>1</sub> to R<sub>4</sub> are, independent of each other, hydroxy or methoxy or methylenedioxy.

23. The compound of claim 1, wherein at least two of R<sub>1</sub>-R<sub>4</sub> are hydroxy.

5

24. The compound of claim 22, wherein said two hydroxy groups are in an ortho relationship to thereby form a pyrocatechol structure.

25. The compound of claim 24, wherein two of R<sub>1</sub>-R<sub>4</sub> are methyl to thereby form said pyrocatechol structure which is dimethylated.

10

26. The compound of claim 24, wherein one of R<sub>1</sub> to R<sub>4</sub> is hydroxy and another is methoxy.

27. The compound of claim 26, wherein said hydroxy and methoxy are in an ortho relationship.

15

28. The compound of claim 1, wherein at least one of R<sub>1</sub> to R<sub>4</sub> is hydroxy or methoxy and at least another of R<sub>1</sub> to R<sub>4</sub> is chloro or bromo,.

20

29. The compound of claim 28, wherein said at least another of R<sub>1</sub> to R<sub>4</sub> is chloro.

30. The compound of claim 28, wherein said hydroxy or methoxy and said chloro or bromo are in an ortho relationship.

25

31. The compound of claim 1, wherein at least two of R<sub>1</sub> to R<sub>4</sub> are methoxy or comprised by methylenedioxy.


32. The compound of claim 1, wherein D is O.


30

33. The compound of claim 1, wherein D is S.


34. The compound of claim 1, in form of a pharmaceutically acceptable acid addition salt.

35. The compound of claim 1 selected from the group consisting of:






Res-4-93




36. The compound of claim 1 selected from the group consisting of:


Res-4-33




Res-4-81




Res-4-95




Res-5-7




Res-5-21




Res-5-32



Res-6-25




Res-6-27



5 37. A compound according to claim 1 which is

Res-4-95



38. A pharmaceutical composition comprising an effective bronchoconstriction relaxing dose of a compound of claim 37 and a pharmaceutically acceptable carrier.

10

39. A pharmaceutical composition comprising an effective bronchoconstriction relaxing dose of a compound of claim 36 and a pharmaceutically acceptable carrier.

5 40. A pharmaceutical composition comprising an effective bronchoconstriction relaxing dose of a compound of claim 35 and a pharmaceutically acceptable carrier.

10 41. A pharmaceutical composition comprising an effective bronchoconstriction relaxing dose of a compound of claim 1 and a pharmaceutically acceptable carrier.

15 42. A method of treating or preventing pulmonary disease characterized by bronchoconstriction, comprising the administration to a person of a bronchoconstriction relaxing dose of the compound of claim 1.

20 43. The method of claim 39, wherein the disease is asthma, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis, bronchiolitis or bronchopulmonary dysplasia.

44. A method of treating or preventing pulmonary disease characterized by bronchoconstriction, comprising the administration to a person of a bronchoconstriction relaxing dose of the compound of claim 35.

25 45. A method of treating or preventing pulmonary disease characterized by bronchoconstriction, comprising the administration to a person of a bronchoconstriction relaxing dose of the compound of claim 36.

30 46. A method of treating or preventing pulmonary disease characterized by bronchoconstriction, comprising the administration to a person of a bronchoconstriction relaxing dose of the compound of claim 37.